WO1993008195A1 - Cyclic peroxyacetal compounds - Google Patents

Cyclic peroxyacetal compounds Download PDF

Info

Publication number
WO1993008195A1
WO1993008195A1 PCT/AU1992/000548 AU9200548W WO9308195A1 WO 1993008195 A1 WO1993008195 A1 WO 1993008195A1 AU 9200548 W AU9200548 W AU 9200548W WO 9308195 A1 WO9308195 A1 WO 9308195A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
compounds
optionally substituted
oxygenation
Prior art date
Application number
PCT/AU1992/000548
Other languages
French (fr)
Inventor
Richard Kingston Haynes
Simone Charlotte Vonwiller
Original Assignee
The University Of Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Sydney filed Critical The University Of Sydney
Priority to AU27672/92A priority Critical patent/AU659505B2/en
Priority to JP5507280A priority patent/JPH07500325A/en
Publication of WO1993008195A1 publication Critical patent/WO1993008195A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/05Alcohols containing rings other than six-membered aromatic rings
    • C07C33/14Alcohols containing rings other than six-membered aromatic rings containing six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/38Alcohols containing six-membered aromatic rings and other rings and having unsaturation outside the aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/30Compounds having groups
    • C07C43/315Compounds having groups containing oxygen atoms singly bound to carbon atoms not being acetal carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/28Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of CHx-moieties
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/29Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00Compounds having —CHO groups
    • C07C47/20Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/225Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/527Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
    • C07C49/553Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings polycyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/46Unsaturated compounds containing hydroxy or O-metal groups containing rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Definitions

  • This invention relates to novel cyclic peroxyacetal compounds and in particular relates to compounds related to qinghaosu (Artemisinin) which is a naturally occurring biologically active compound.
  • the present invention provides novel compounds which are structurally similar to the naturally occurring biologically active compound qinghaosu (Artemisinin) which has the following formula:
  • Qinghaosu is a potent anti-malarial which has been successfully used to treat patients suffering from malaria.
  • the re-emergence of strains of malaria resistant to conventional (chloroquine) therapy is posing a world-wide problem and indeed, there is no universally acceptable cure at the present time.
  • Qinghaosu occurs to the extent of about 0.1% (dry weight) in an annual shrub, qinghao or Artemisia a nnua, which grows in most provinces of China.
  • Unfortunately the world demand for qinghaosu far exceeds the supply, and there is considerable pressure to develop bioactive analogues and derivatives or to develop alternative sources for the compound.
  • novel compounds have activities superior to that of qinghaosu and furthermore these compounds will be suitable for preparing conjugate drugs for the treatment of malaria and other parasitic and viral diseases.
  • novel compounds can also be used as building blocks because of their reactive side chain and other active drugs can be linked via these side chains to form conjugate drugs.
  • the present invention provides compounds of general formula (I), pharmaceutically acceptable salts thereof or stereoisomeric forms thereof
  • n is an integer from 1-6
  • X -(CR 1 R 2 ) r -R 3 where r is an integer from 1-10 and where r > 1, optionally at least 1 carbon atom can be replaced by O, S or N;
  • R 1, R 2 and R 3 are independently selected from
  • R and R' are independently selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl or optionally substituted arylalkyl wherein the optional substituents are as defined above.
  • Preferred compounds of formula (I) have the following structural formulae:
  • the oxygenation step is basically, the process described in PCT/AU90/00456 (WO 91/04970) and that disclosure is incorporated herein by reference.
  • the oxygenation is preferably carried out as a "one-pot" reaction and involves oxygenation of a compound of formula (II) to provide a hydroperoxide derivative and without isolation further oxygenation in the presence of one or more oxygenating metal catalysts to give a compound of formula (I).
  • the oxygenation of the hydroperoxy compound in the presence of one or more catalysts provides an oxygenation-cleavage-cyclization reaction to give the cyclic peroxyacetal compounds of formula (I).
  • the oxygenation-cleavage-cyclization reaction is typically carried out by treating with one or more transition metal catalysts such as Cu(OSO 2 CF 3 ) 2 , Cu(II) propionate, copper (II) 2-ethylhexanoate, other copper (II) carboxylic salts, and various iron (III) salts such as
  • Fe(phenanthroline) 3 (PF 6 ) 3 Fe(phenanthroline) 3 (PF 6 ) 3 .
  • Other catalysts that may be used are cobalt (II) and cobalt (III) salts.
  • this reaction is carried out in a solvent such as a mixture of acetonitrile and dichloromethane and by treating with one of the above mentioned catalysts, or with a combination of the copper and iron catalysts.
  • a solvent such as a mixture of acetonitrile and dichloromethane and by treating with one of the above mentioned catalysts, or with a combination of the copper and iron catalysts.
  • suitable solvents include hexane, ethyl acetate and the like.
  • Preferred solvents for the Grignard addition reactions are diethyl ether, or THF but any other solvent such as benzene or other ether solvent would be suitable.
  • the reaction is typically initially carried out at the temperature of 0°-5°C and continued at room temperature.
  • MeOH may also be used and bases such as Na 2 CO 3 , K 2 CO 3 or
  • NaHCO 3 can also be used.
  • the reactions are preferably carried out at room temperature.
  • Oxidative degradation is preferably carried out using cupric acetate, 2,2'-bipyridyl and DABCO in DMF under atmospheric oxygen at between about 70°-75°C for about 12 hours.
  • the reduction is preferably carried out in methanol or other alcoholic solvent with NaBH 4 at about 0°C.
  • Other reducing agents with appropriate solvents may also be used *
  • the starting compound for process A is the aldehyde 2 having the following structure
  • the aldehyde is preferably prepared from qinghao acid which has the following formula:
  • Qinghao acid occurs to the extent of 1-3% (dry weight) in Artemisia an nua, which is much greater than the natural occurrence of qinghaosu and is easily extracted from the plant.
  • the starting material for the process B is preferably qinghao acid which is oxygenated to provide dehydro- qinghaosu of the following formula
  • the starting material for process C is also preferably the aldehyde having the structural formula 2.
  • This aldehyde is typically prepared from qinghao acid by carrying out the following steps.
  • compositions comprising a compound of formula (I), a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof in a pharmaceutically acceptable carrier and/or diluent.
  • Pharmaceutical compositions containing a compound of formula (I) as the active ingredient in admixture with a pharmaceutically acceptable carrier or diluent can be prepared according to conventional pharmaceutical formulating techniques.
  • the carrier may be of any form depending on the form of preparation desired for administration, eg intravenous, oral or parenteral.
  • the present invention provides a method of treatment or prophylaxis of parasitic or viral diseases in a mammal comprising administering to the mammal a compound of formula (I), a pharmaceutically acceptable salt thereof or a stereoisomeric form thereof.
  • the aldehyde (50.6 mg; 0.23 mmol) was dissolved in diethyl ether (3 ml) and treated with ethyl magnesium bromide in ether with cooling in an ice bath. The whole was then stirred at room temperature for 30 min. before being quenched with aqueous ammonium chloride solution
  • Mass spectrum m/z 379 (M-1, 0.5%), 335 (10), 317 (11), 289 (16), 189 (47), 162 (100), 143 (43), 103 (66), 85 (52), 81 (61), 69 (53), 55 (66), 47 (57), 31 (62).
  • Methylmagnesium iodide was prepared by treating magnesium turnings (80 mg; 3.3 mmol) in dry. ether (4 ml) with methyl iodide (0.17 ml; 2.8 mmol) under gentle reflux. A solution of the methyl ester of dihydroqinghao acid (138.3 mg; 0.55 mmol) in ether (3 ml) was then added dropwise at room temperature. The reaction mixture was heated under gentle reflux for a further 2 h before being cooled in ice. Aqueous ammonium chloride solution was added and the whole was extracted with ether. The combined ether extracts were washed with brine, dried ( Na 2 SO 4 ) and evaporated to dryness to give the crude alcohol.
  • Mass spectrum m/z 232 (M - H 2 O, 9%), 217 (7), 189 (25), 163 (36), 162 (100), 147 (17), 121 (13), 107 (17), 95 (14), 81 (27), 59 (40), 41 (20).
  • Dihydroqinghao alcohol (1) (43.9 mg; 0.20 mmol) was mixed with acetonitrile (2.5 ml) and irradiated under oxygen at -30° for 3 h in the presence of Rose Bengal sensitiser.
  • the resulting hydroperoxide solution was then diluted with dichloromethane (5 ml) and treated with Cu(OTf) 2 (0.020 mmol, 0.1 M in acetonitrile) at -20°.
  • the reaction mixture was stirred at -15° for a further 40 min. and was then allowed to warm to room temperature over 20 min. before being cooled to -10°. Water was added and then the whole was extracted with ether.
  • the ethyl alcohol (3) (77.9 mg; 0.31 mmol) was dissolved in dichloromethane (1 ml) and acetonitrile (2 ml) and irradiated under oxygen at -30° for 4 h in the presence of Rose Bengal sensitiser.
  • the resulting solution of hydroperoxides was then diluted with dichloromethane (7 ml) and treated with Cu(OTf) 2 (0.031 mmol, 0.1 M in acetonitrile) at -20°.
  • the mixture was kept at -20° for a further 40 min. and then allowed to warm to room temperature over 20 min. before being cooled to -10°. Water was added and then the whole was extracted into ether.
  • Mass spectrum m/z 296 (M + , 0.7%), 278 (M-H 2 O, 1), 264 (M-O 2 , 24), 206 (100), 193 (33), 182 (45), 165 (35), 124 (72), 95 (35), 81 (34), 69 (58), 55 (92), 43 (90), 41 (63), 29 (38).
  • Mass spectrum m/z 326 (M + -H 2 O, 0.4%), 312 (M-O 2 , 13), 298 (12), 254 (16) , 240 (23) , 182 (100) , 124 (68) , 118 (52) ,
  • the dimethyl alcohol (8) (53 mg; 0.21 mmol) was submitted to the same conditions as described in a). Dimethyl deoxoqinghaosu (14) was then isolated by flash chromatography on silica (ether/light petroleum/ 20:80) as a viscous oil which slowly crystallised (22 mg; 35%).
  • Dehydroqinghaosu (16.7 mg; 59.5 ⁇ mol) was treated with methyl thioglycolate (5.3 ⁇ l; 59.5 ⁇ mol) and triethylamine (4 ⁇ l) in chloroform (2 ml) for 3 d as described above.
  • Triethylamine (7.9 ⁇ l; 57 ⁇ mol) was added to a stirred solution of dehydroqinghaosu (15.9 mg; 57 ⁇ mol) and a suspension of N-acetyl-L-cysteine (9.3 mg; 57 ⁇ mol) in chloroform (3 ml). Deprotonation of the cysteine caused it to go into solution.
  • the reaction mixture was stirred under nitrogen for 24 h and then for a further 24 h allowing the solvent to evaporate away slowly. Water was added and then the whole was extracted once with ether. The aqueous layer was separated and then acidified with 1 M hydrochloric acid in the presence of ether and extracted three times with more ether.
  • the major alcohol epimer (24b) (55.8 mg; 0.27 mmol) in acetonitrile (2 ml) and dichloromethane (1 ml) was irradiated under oxygen at -30° for 4 h in the presence of Rose Bengal sensitiser.
  • the resulting hydroperoxide solution was then diluted with dichloromethane (7 ml) and treated with Cu(OTf) 2 ( 0.027 mmol, 0.1 M in acetonitrile) as described for the preparation of the deoxoqinghaosu derivatives.
  • FC27 strain from Madang, Papua New Guinea (chloroquine sensitive)

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polymerization Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compounds of general formula (I), pharmaceutically acceptable salts thereof or stereoisomeric forms thereof, wherein 1 = 1, 2 or 3, n is an integer from 1-6, where X is independently selected from H, =O, =CH2, aryl, COR, OR, COOR or X = -(CR1R2)r-R3 where r is an integer from 1-10 and where r > 1, optionally at least 1 carbon atom can be replaced by O, S or N; R1, R2 and R3 are independently selected from H; alkyl, alkenyl, alkynyl, aryl, each optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, aryl, halogen, OR, CF3, NO2, COOR, NRR', SR, COR, CONRR', SO3R, SO2NRR', SR, SOR, and SO2R, where R and R' are independently selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl or optionally substituted arylalkyl wherein the optional substituents are as defined above. These compounds are structurally similar to the naturally occurring biologically active compound qinghaosu (Artemisinin) and some compounds have activities superior to that of qinghaosu.

Description

CYCLIC PEROXYACETAL COMPOUNDS
Technical Field
This invention relates to novel cyclic peroxyacetal compounds and in particular relates to compounds related to qinghaosu (Artemisinin) which is a naturally occurring biologically active compound.
Background of the Invention
The present invention provides novel compounds which are structurally similar to the naturally occurring biologically active compound qinghaosu (Artemisinin) which has the following formula:
Figure imgf000003_0001
Qinghaosu is a potent anti-malarial which has been successfully used to treat patients suffering from malaria. The re-emergence of strains of malaria resistant to conventional (chloroquine) therapy is posing a world-wide problem and indeed, there is no universally acceptable cure at the present time. Qinghaosu occurs to the extent of about 0.1% (dry weight) in an annual shrub, qinghao or Artemisia a nnua, which grows in most provinces of China. Unfortunately, the world demand for qinghaosu far exceeds the supply, and there is considerable pressure to develop bioactive analogues and derivatives or to develop alternative sources for the compound.
Some of the novel compounds have activities superior to that of qinghaosu and furthermore these compounds will be suitable for preparing conjugate drugs for the treatment of malaria and other parasitic and viral diseases.
The novel compounds can also be used as building blocks because of their reactive side chain and other active drugs can be linked via these side chains to form conjugate drugs.
Disclosure of the Invention
In one aspect, the present invention provides compounds of general formula (I), pharmaceutically acceptable salts thereof or stereoisomeric forms thereof
Figure imgf000004_0001
wherein
l = 1, 2 or 3
n is an integer from 1-6
where X is independently selected from
H, =O,=CH2, aryl, COR, OR, COOR or
X = -(CR1R2)r-R3 where r is an integer from 1-10 and where r > 1, optionally at least 1 carbon atom can be replaced by O, S or N;
R1, R2 and R3 are independently selected from
H; alkyl, alkenyl, alkynyl, aryl, each optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, aryl, halogen, OR, CF3, NO2, COOR, NRR',
SR, COR, CONRR', SO3R, SO2NRR', SR, SOR, and SO2R, where R and R' are independently selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl or optionally substituted arylalkyl wherein the optional substituents are as defined above.
Preferred compounds of formula (I) have the following structural formulae:
Figure imgf000005_0001
In another aspect the present invention provides a process for preparing compounds of formula (I), pharmaceutically acceptable salts thereof or stereoisomeric forms thereof comprising: (A) carrying out at least one addition reaction on a compound of formula (II) having a -C=O functionality
Figure imgf000006_0001
to provide another compound of formula (II) with an alcoholic functionality at the (C)1-(V)r group and then followed by oxygenation to give a compound of formula (I);
where V is as defined for X; r and l are as defined above; (B) directly oxygenating a compound of formula (II) where there is a carboxylic functionality at the
(C)l-(V)r reactive chain and also a further functional group to facilitate subsequent addition reaction, to provide compounds of formula (I) and then carrying out a suitable addition reaction to provide the required side chain; or
(C) for compounds of formula (I) where l=1; carrying out one or more of the following steps on a compound of general formula (II): (i) oxidative degradation and
(ii) reduction followed by oxygenation to give compounds of formula (I). Best Mode of Carrying out the Invention
The oxygenation step is basically, the process described in PCT/AU90/00456 (WO 91/04970) and that disclosure is incorporated herein by reference. The oxygenation is preferably carried out as a "one-pot" reaction and involves oxygenation of a compound of formula (II) to provide a hydroperoxide derivative and without isolation further oxygenation in the presence of one or more oxygenating metal catalysts to give a compound of formula (I). The oxygenation of the hydroperoxy compound in the presence of one or more catalysts provides an oxygenation-cleavage-cyclization reaction to give the cyclic peroxyacetal compounds of formula (I).
The oxygenation-cleavage-cyclization reaction is typically carried out by treating with one or more transition metal catalysts such as Cu(OSO2CF3)2, Cu(II) propionate, copper (II) 2-ethylhexanoate, other copper (II) carboxylic salts, and various iron (III) salts such as
Fe(phenanthroline)3(PF6)3. Other catalysts that may be used are cobalt (II) and cobalt (III) salts. Preferably this reaction is carried out in a solvent such as a mixture of acetonitrile and dichloromethane and by treating with one of the above mentioned catalysts, or with a combination of the copper and iron catalysts. Other suitable solvents include hexane, ethyl acetate and the like.
Preferred solvents for the Grignard addition reactions are diethyl ether, or THF but any other solvent such as benzene or other ether solvent would be suitable.
The reaction is typically initially carried out at the temperature of 0°-5°C and continued at room temperature.
Other addition reactions are typically carried out in
CHCI3 and CH2Cl2 with an amine base. MeOH and aqueous
MeOH may also be used and bases such as Na2CO3, K2CO3 or
NaHCO3 can also be used. The reactions are preferably carried out at room temperature.
Oxidative degradation is preferably carried out using cupric acetate, 2,2'-bipyridyl and DABCO in DMF under atmospheric oxygen at between about 70°-75°C for about 12 hours. The reduction is preferably carried out in methanol or other alcoholic solvent with NaBH4 at about 0°C. Other reducing agents with appropriate solvents may also be used*
Preferably the starting compound for process A is the aldehyde 2 having the following structure
Figure imgf000008_0001
This is preferably treated with Grignard reagents or other organometallic reagents such as those derived from lithium, copper or zinc to provide compounds of the following formulae:
Figure imgf000009_0003
which are then oxygenated to provide the corresponding compounds of formula (I):
Figure imgf000009_0002
The aldehyde is preferably prepared from qinghao acid which has the following formula:
Figure imgf000009_0001
Qinghao acid occurs to the extent of 1-3% (dry weight) in Artemisia an nua, which is much greater than the natural occurrence of qinghaosu and is easily extracted from the plant.
The starting material for the process B is preferably qinghao acid which is oxygenated to provide dehydro- qinghaosu of the following formula
Figure imgf000010_0001
on which is carried out various addition reactions to provide compounds of formula (I). The starting material for process C is also preferably the aldehyde having the structural formula 2. This aldehyde is typically prepared from qinghao acid by carrying out the following steps.
1. methylation to provide the unsaturated methyl ester;
2. reduction to provide the saturated methyl ester;
3. reduction to provide the alcohol;
4. oxidation to provide the aldehyde.
The skilled addressee would understand that the process of the invention may result in one or more stereogenic (chiral) centres being formed resulting in stereoisomers. Thus it is to be understood that the present invention includes within its scope the preparation of stereoisomers and also encompasses any isomers per se or mixture thereof.
Most of the starting compounds of formula (II) are also novel and form part of the present invention. Accordingly, in yet another aspect, the present invention provides compounds of general formula (II)
Figure imgf000011_0001
wherein V is as defined for and are as hereinbefore defined; provided that the (C)l-(V)r group is not CH(CH3)CH2OH and CH(CH3)C(=O)H. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof in a pharmaceutically acceptable carrier and/or diluent. Pharmaceutical compositions containing a compound of formula (I) as the active ingredient in admixture with a pharmaceutically acceptable carrier or diluent can be prepared according to conventional pharmaceutical formulating techniques. The carrier may be of any form depending on the form of preparation desired for administration, eg intravenous, oral or parenteral.
In yet another aspect, the present invention provides a method of treatment or prophylaxis of parasitic or viral diseases in a mammal comprising administering to the mammal a compound of formula (I), a pharmaceutically acceptable salt thereof or a stereoisomeric form thereof.
Specific embodiments of the present invention are illustrated by the following preparative examples. It will be understood, however, that the invention is not confined to the specific limitations set forth in the individual examples. PREPARATION OF STARTING COMPOUNDS
Preparation of Derivatives of Qinghao Acid
Example 1
a) Dihydroqinghao alcohol (1) and dihydroqinghao aldehyde (2)
Figure imgf000012_0001
Figure imgf000012_0002
Qinghao acid (307 mg; 1.31 mmol) was firstly converted into its methyl ester by heating it with dimethyl sulfate (198 mg; 1.57 mmol; 0.15 ml) and potassium carbonate (199 mg; 1.44 mmol) in acetone (15 ml) under gentle reflux for 2 h. The crude product was then dissolved in methanol (7 ml) and treated with sodium borohydride (72 mg; 1.90 mmol) in the presence of nickel boride, which was preformed from NiCl2.6H2O (30 mg; 0.13 mmol), at -30° to give the saturated ester after acidic workup. This was then dissolved in diethyl ether (7 ml) and treated with lithium aluminium hydride (1 M solution in THF), with cooling in ice, until complete conversion to the saturated alcohol was observed by t.l.c. The reaction mixture was heated under gentle reflux for 40 min. before being cooled and quenched with ethyl acetate (5 ml) and water (2 ml). Sodium sulfate was added to the stirred mixture until the excess water had been absorbed and it was then removed by filtration, and washed with more ether. The filtrate was evaporated to dryness to give dihydroqinghao alcohol (1). The pure alcohol could be isolated by flash chromatography (ether/light petroleum, 40:60) in greater than 90% yield, 1H NMR spectrum (200 MHz, CDCl3) δ 0.864 (3H, d, J4-Me,4 = 6.4 Hz, 4-CH3), 0.997 (3H, d, J3,,2, = 6.8 Hz, H3'), 1.630 (3H, m, 7-CH3), 2.475 (1H, br s, Wh/2 = 11.5 Hz, OH), 3.522 (1H, dd, Jgem=10.6, J1 ,,2, = 6.2 Hz, H1'), 3.740 (1H, dd, Jgem = 10.6, J1,,2, =3.3 Hz, E1'), 5.218 (1H, m, H8). However, in general, the residue after evaporation of the filtrate, without purification, was immediately submitted to Swern oxidation conditions. Thus, DMSO (0.37 ml; 5.2 mmol) in dichloromethane (2 ml) was added dropwise to a solution of oxalyl chloride (0.23 ml; 2.6 mmol) in dichloromethane (8 ml) at between -50° and -60°. After 5 min. the crude alcohol (288 mg) in dichloromethane (4 ml) was added dropwise at the same temperature and after 15 min. triethylamine (1.09 ml; 7.8 mmol) was added. Stirring was continued at -60° for 5 min. and then the whole was allowed to warm to room temperature over 20 min. Aqueous workup afforded the aldehyde (2) which was submitted to flash chromatography (ether/light petroleum, 5:95) to give a colourless oil [228 mg; 79% from qinghao acid]. The aldehyde was found to be a 6.2:1 mixture of diastereomers and as such was used to prepare the other qinghao acid derivatives. 1H NMR spectrum (200 MHz, CDCl3) δ 0.877 (3H, d, J4-Me,4 = 6.3 Hz, 4-CH3), 1.067 (3H, d, J3,2, = 7.0 Hz, H3'), 1.638 (3H, m, 7-CH3), 5.132 (1H, m, H8), 9.588 (1H, d, J1,2, = 4.2 Hz, H1').
Example 2
b) Ethyl alcohol (3)
Figure imgf000013_0001
The aldehyde (50.6 mg; 0.23 mmol) was dissolved in diethyl ether (3 ml) and treated with ethyl magnesium bromide in ether with cooling in an ice bath. The whole was then stirred at room temperature for 30 min. before being quenched with aqueous ammonium chloride solution
(ice bath). Acidic workup gave the crude alcohol which was purified by flash chromatography (ether/light petroleum, 20:80) as a colourless viscous oil (48.8 mg; 85%) and as a 85:15 mixture of epimers. vmax 3611 m, 3466 br m (OH), 3011 m, 2964 s, 2924 vs, 2872 s, 1456 m, 1380 m, 1236 w, 982 m, 951 m, cm'1. 1H NMR spectrum (200 MHz, CDCl3) d 0.846 (3H, d, J1,,2, = 6.5 Hz, H1'), 0.868 (3H, d, J4-Me,4 = 6.3 Hz, 4-CH3), 0.955 (3H, t, J5,,4, = 7.4 Hz, H5'), 1.632 (3H, m, 7-CH3), 2.479 (1H, br s, Wh/2 = 11.3 Hz, OH), 3.736 (1H, m, H3'), 5.188 (1H, m, H8). Mass spectrum: m/z 250 (M, 2%), 232 (M-H20, 22), 189 (37), 162 (100), 81 (41). Example 3
c) Phenyl alcohol (4)
Figure imgf000014_0001
The aldehyde (48 mg; 0.22 mmol) in ether (4 ml) was treated with phenyl magnesium bromide in ether as described above. Flash chromatography (ether/light petroleum, 20:80) of the crude product gave the phenyl alcohol (4) as a colourless viscous oil (55.8 mg; 86%). This was found to be a 76:24 mixture of epimers with respect to the hydroxyl group. Partial 1H NMR spectrum (200 MHz, CDCI3, *denotes minor epimer) δ *2.340 (1H, br s, Wh/2 = 11.3 Hz, OH), 2.512 (1H, br S, Wh/2=11.3 Hz, OH), *5.043 (1H, d, J1,,2, = 4.3 Hz, H1'), 5.107 (1H, m, H1'), 5.171 (1H, m, H8), *5.277 (1H, m, H8).
Example 4
d) Allyl alcohol (5)
Figure imgf000014_0002
The aldehyde (95.1 mg; 0.43 mmol) in ether (5 ml) was treated with allylmagnesium bromide in ether as described above. Flash chromatography (ether/light petroleum, 20:80) of the crude product gave the allyl alcohol (5) as a colourless viscous oil (99.7 mg; 88%) and as an approximately 55:45 mixture of epimers. 1H NMR spectrum (200 MHz, CDCl3, *denotes minor epimer) δ 0.865 (3H, d, J4-Me,4 = J1,,2, = 6-2 Hz, 4"CH3, H1'), *0.881 (3H, d, J4-Me,4 = 6.5 Hz, 4-CH3), *0.897 (3H, d, J1,2, = 6.7 Hz, H1'), 1.62 (3H, m, 7-CH3, *7-CH3), 2.48 (1H, br s, Wh/2 = 12 Hz, OH, *OH), 3.83-3.95 (1H, m, H3', *H3'), 5.07-5.29 (3H, m, 2 × H6', 2 × *H6', H8, *H8), 5.73-5.97 (1H, m, H5', *H5').
Example 5
e) Hydroxy acetals (6a) and (6b)
Figure imgf000015_0001
Figure imgf000015_0002
The aldehyde (210.7 mg; 0.96 mmol) in ether (8 ml) was treated with the Grignard reagent (1.5 equiv.), derived from 5-bromopentanaldehyde diethyl acetal and magnesium in THF, with cooling in an ice bath. The whole was stirred at room temperature for 30 min. before being quenched with aqueous ammonium chloride. The product was extracted into ether, and the ether extracts were washed with brine and dried (Na2SO4). Evaporation of the solvents under reduced pressure left a pale liquid which upon purification by flash chromatography (ether/light petroleum, 35:65) gave the hydroxy diethyl acetal as a colourless viscous oil (309 mg; 85%) and as a ca. 88:12 mixture of the (2'R,3'R)- and (2'R,3'S)-diastereomers,
(6a) and (6b) respectively. These were separated by h.p.l.c. (ethyl acetate/light petroleum, 13:87, Whatman Partisil 10, preparative) to give the (2'R,3'S)-isomer
(6a) as the first to be eluted:- [α]D 20 +2.1° (c, 0.43,
CHCl3). vmaχ (CHCI3) 3536 w, 3600-3100 br s (OH), 2977 S, 2931 s, 2870 s, 1454 m, 1377 m, 1236 w, 1126 S, 1057 s, 993 m cm-1. 1H NMR spectrum (200 MHz, CHCl3) δ 0.845 (3H, d, J1,,2, = 6.4 Hz, H1'), 0.866 (3H, d, J4-Me,4 = 6.3 Hz, 4- CH3), 1.205 (6H, t, J = 7.1 Hz, CH3CH2O), 1.631 (3H, m, 7- CH3), 2.471 (1H, br s, Wh/2 = 11.5 Hz, OH), 3.41-3.72 (4H, m, CH3CH2O), 3.82 (1H, m, H3'), 4.491 (1H, t, J8,,7, = 5.6 Hz, H8'), 5.180 (1H, m, H8). Mass spectrum: m/z 379 (M-1, 0.5%), 335 (10), 317 (11), 289 (16), 189 (47), 162 (100), 143 (43), 103 (66), 85 (52), 81 (61), 69 (53), 55 (66), 47 (57), 31 (62).
The next to be eluted was the (2'R,3'S)-isomer (6b):- [α]D 20 -7.3° (c, 0.30, CHCl3) . vmax (CHCl3) 3535 w, 3600 -
3100 br s (OH), 2977 S, 2934 s, 2873 s, 1455 m, 1377 m,
1234 w, 1126 s, 1057 s, 1002 m cm-1. 1H NMR spectrum (200
MHz, CHCl3) δ 0.862 (6H, d, J1,,2 = J4-Me,4 = 6.6 Hz, H1',
4-CH3), 1.207 (6H, t, J = 7.1 Hz, CH3CH2O), 1.625 (3H, m, 7-CH3), 2.461 (1H, br s, Wfa/2 = 11.2 Hz, OH), 3.42-3.73
(4H, m, CH3CH2O), 3-82 (1H, m, H3'), 4.492 (1H, t, J8,,7, =
5.6 Hz, H81), 5.244 (1H, m, H8). Mass spectrum: m/z 379
(M-1, <0.1%), 335 (1), 317 (2), 189 (17), 162 (100), 143
(15), 103 (52), 98 (27), 95 (19), 85 (23), 81 (37), 75 (21), 69 (21), 55 (32), 43 (25), 31 (37).
Example 6
f) Hydroxy acid (7a) and (7b)
Figure imgf000016_0001
Figure imgf000016_0002
The (2'R,3'R)-hydroxy acetal (6a) (40.4 mg; 0.11 mmol) was dissolved in THF (2 ml) and treated with aqueous HCl (1 M, 1 ml) with rapid stirring at room temperature. After 30 min. the whole was extracted with ether and the combined extracts were washed with brine and dried (Na2SO4). Evaporation of the solvents left the crude aldehyde which was then dissolved in ethanol (1 ml). This was added to a stirred solution of silver nitrate ( 54 mg; 0.32 mmol) in water (0.12 ml). The resulting mixture was cooled in an ice bath, treated with aqueous KOH solution (34%, 0.105 ml), and then stirred at room temperature for 2 h. The black silver precipitate was filtered off, washing with water, and the filtrate was acidified with 3 M HCl with cooling in ice. The acidic solution was extracted with ether and the combined extracts were dried (MgSO4) and evaporated to dryness. Purification of the residue by chromatography on silicic acid (ether/light petroleum, 1:1) afforded the (2'R,3'R)-hydroxy acid (7a) as a colourless viscous oil (31.2 mg; 91% overall). 1H NMR spectrum (200 MHz, CDCI3) δ 0.864
(3H, d, J4-Me,4 = 6.3 Hz' 4-CH3), 0.881 (3H, d, J1',2' = 6-3 Hz, H1'), 1.648 (3H, m, 7-CH3), 2.390 (2H, t, J7,,6, = 7.3
Hz, H7'), 2.480 (1H, br s, Wh/2 = 12.8 Hz, OH), 3.86 (1H, m, H3'), 5.185 (1H, m, H8), 5.969 (1H, br s, Wh/2=88.5 Hz,
COOH). Similarly, the (2'R,3'S)-hydroxy acetal (6b)
(30.4 mg; 80 μmol) was converted into the (2'R,3'S)-hydroxy acid (7b) (24 mg; 93%). 1H NMR spectrum (200 MHz,
CDCI3) δ 0.866 (3H, d, J1,,2, = J4-Me,4=6-8 Hz' H1'' 4-CH3), 1.630 (3H, m, 7-CH3), 2.382 (2H, t, J7,,6, = 7.3 Hz, H7'), 2.461 (1H, br s, Wh/2 = 11.9 Hz, OH), 3.85 (1H, m, H3'), 4.435 (1H, br s, Wh/2 - 113 Hz, COOH), 5.238 (1H, m, H8). Example 7
g) Dimethyl alcohol (8)
Figure imgf000017_0001
Methylmagnesium iodide was prepared by treating magnesium turnings (80 mg; 3.3 mmol) in dry. ether (4 ml) with methyl iodide (0.17 ml; 2.8 mmol) under gentle reflux. A solution of the methyl ester of dihydroqinghao acid (138.3 mg; 0.55 mmol) in ether (3 ml) was then added dropwise at room temperature. The reaction mixture was heated under gentle reflux for a further 2 h before being cooled in ice. Aqueous ammonium chloride solution was added and the whole was extracted with ether. The combined ether extracts were washed with brine, dried ( Na2SO4) and evaporated to dryness to give the crude alcohol. This was purified by flash chromatography (ether/light petroleum, 15:85) to give the dimethyl alcohol as a crystalline solid (113 mg; 82%), m.p. 52- 54°. 1H NMR spectrum (200 MHz, CDCI3) δ 0.855 (3H, d, J4- Me,4 = 6.4 Hz, 4-CH3), 0.926 (3H, d, J1,,2, = 6.9 Hz, H1'), 1.190 (3H, s, H4' or 3-CH3), 1.249 (3H, s, H4' or 3-CH3), 0.87 - 2.0 (13H, m), 1.628 (3H, br m, Wh/2 = 5.5 Hz, 7- CH3), 2.526 (1H, br s, Wh/2 = 11.6 Hz, OH), 5.280 (1H, br m, Wh/2 = 6.8 Hz, H8). Mass spectrum: m/z 232 (M - H2O, 9%), 217 (7), 189 (25), 163 (36), 162 (100), 147 (17), 121 (13), 107 (17), 95 (14), 81 (27), 59 (40), 41 (20).
PREPARATION OF FINAL COMPOUNDS
Preparation of Deoxoqinghaosu Derivatives
Example 8
a) Deoxoqinghaosu (9)
Figure imgf000018_0001
Dihydroqinghao alcohol (1) (43.9 mg; 0.20 mmol) was mixed with acetonitrile (2.5 ml) and irradiated under oxygen at -30° for 3 h in the presence of Rose Bengal sensitiser. The resulting hydroperoxide solution was then diluted with dichloromethane (5 ml) and treated with Cu(OTf)2 (0.020 mmol, 0.1 M in acetonitrile) at -20°. The reaction mixture was stirred at -15° for a further 40 min. and was then allowed to warm to room temperature over 20 min. before being cooled to -10°. Water was added and then the whole was extracted with ether. The combined extracts were washed with brine, dried (MgSO4) and evaporated to dryness. The residue was purified by flash chromatography (ether/light petroleum, 40:60) to give deoxoqinghaosu (9) as a crystalline solid (19 mg;
36%). 1H NMR spectrum (200 MHz, CDCI3) δ 0.780 (3H, d,
J9-Me,9=7.2 Hz' 9-CH3), 0.963 (3H, d, J6-Me,6=5.9 Hz, 6-CH3), 1.43 (3H, s, 3-CH3), 3.449 (1H, dd, Jgem=11.7, J10,9=11.7
Hz, H10), 3.731 (1H, br dd, Jgem=11.7, J10,9=4 Hz, H10), 5.200 (1H, S, H12).
Example 9
b) Ethyl Deoxoqinghaosu (10)
Figure imgf000019_0001
The ethyl alcohol (3) (77.9 mg; 0.31 mmol) was dissolved in dichloromethane (1 ml) and acetonitrile (2 ml) and irradiated under oxygen at -30° for 4 h in the presence of Rose Bengal sensitiser. The resulting solution of hydroperoxides was then diluted with dichloromethane (7 ml) and treated with Cu(OTf)2 (0.031 mmol, 0.1 M in acetonitrile) at -20°. The mixture was kept at -20° for a further 40 min. and then allowed to warm to room temperature over 20 min. before being cooled to -10°. Water was added and then the whole was extracted into ether. The combined extracts were washed with brine, dried (MgSO4) and evaporated to dryness. The residue was fractionated by flash chromatography (ether/light petroleum, 10:90) to give ethyl deoxoqinghaosu (10) as a waxy solid (31.1 mg; 34%) and essentially only as the ß- epimer with respect to the ethyl group, % NMR spectrum (400 MHz, CDCl3) δ 0.860 (3H, d, JMe,9=7.6 Hz, 9-CH3), 0.958 (3H, d, JMe,6=6.0 Hz, 6-CH3), 1-034 (3H, t, J2.,1,=7.3 Hz, H2'), 1.426 (3H, s, 3-CH3), 2.687 (1H, ddq, J9,Me=7.5, J9,8a=7.5, J9,10=6.1 Hz, H9), 4-036 (1H, ddd, J10,1,=10.6, J10,9=6.0, J10,1,=2.8 Hz, H10), 5.28 (1H, s, H12). 13C NMR spectrum (50 MHz, CDCI3) δ 12.105 (C2'), 13.01 (9-CH3), 20.20 (6-CH3), 22.27 (C8), 24.87 (C1' or C5), 24.87 (C1' or C5), 26.13 (3-CH3), 30.25 (C9), 34.48 (C7), 36.57
(C4), 37.42 (C6), 44.45 (C8a), 52.03 (C5a), 77.64 (C10),
81.14 (C12a), 88.88 (C12), 103.14 (C3). Mass spectrum: m/z 296 (M+, 0.7%), 278 (M-H2O, 1), 264 (M-O2, 24), 206 (100), 193 (33), 182 (45), 165 (35), 124 (72), 95 (35), 81 (34), 69 (58), 55 (92), 43 (90), 41 (63), 29 (38).
Example 10
c) Phenyl Deoxoqinghaosu (11)
Figure imgf000020_0001
The phenyl alcohol (4) (55.4 mg; 0.19 mmol) was dissolved in dichloromethane (0.5 ml) and acetonitrile (1.5 ml) and photooxygenated at -30° for 3 h. Dilution of the reaction mixture with dichloromethane and treatment with Cu(OTf)2 as described above followed by purification of the crude product by flash chromatography (ether/light petroleum, 7:93) afforded phenyl deoxoqinghaosu (11) as a viscous oil (17.4 mg; 27%) and exclusively as the ß-epimer with respect to the phenyl group, % NMR spectrum (200 MHz, CDCI3) δ 0.508 (3H, d, JMe,9=7-7 Hz, 9-CH3), 0.987 (3H, d, JMe,6=5.6 Hz, 6-CH3), 1.383 (3H, s, 3- CH3) ,2.749 (1H, ddq, J9,Me=7.1, Jg,8a=7.1, J9,10=6.7 Hz, H9) , 5.577 (1H, S, H12), 5.723 (1H, d, J10,9=6.7 Hz, H10, 7.15- 7.34 (5H, m, C6H5) . 13C NMR spectrum (50 MHz, CDCl3) d 13.75 (9-CH3), 19.98 (6-CH3) , 24.84 (C5 or C8), 25.01 (C5 or C8) , 25.81 (3-CH3) , 32.21 (C9) , 34.29 (C7) , 36.77 (C4), 37.60 (C6), 43.59 (C8a), 51.59 (C5a), 73.14 (C10), 81.26 (C12a), 90.95 (C12), 102.38 (C3), 126.23, 126.38, 127.80 (C6H5 Cmeta, Cpara, Cortho) , 141.15 (C6H5 Cipso) . Mass spectrum: m/z 326 (M+-H2O, 0.4%), 312 (M-O2, 13), 298 (12), 254 (16) , 240 (23) , 182 (100) , 124 (68) , 118 (52) ,
105 (31) , 91 (32) , 55 (23) , 43 (46) , 28 (61) .
Example 11
d) Allyl Deoxoqinghaosu (12)
Figure imgf000021_0001
The allyl alcohol (5) (46 mg; 0.18 mmol) was submitted to the same conditions as described in a) . Allyl deoxoqinghaosu (12) was then obtained by flash chromatography (ether/light petroleum, 10:90) as a crystalline solid (18.3 mg; 36%) and as a 1:3 mixture of α- and ß-epimers with respect to the allyl group, H NMR spectrum (200 MHz, CDCl3) δ 0.782 [3H, d, JMe9=7.2 Hz, 9-CH3(α)], 0.888 [3H, d, JMe,9=7-6 Hz, 9-CH3(ß)], 0.951 [3H, d, JMe,6=6·0 Hz, 6-CH3(α)], 0.965 [3H, d, JMe,6=5.8 Hz, 6-CH3(ß)], 1.417 (3H, s, 3-CH3), 2.69 [1H,ddq, J98a=7.9, J9,Me=7.3, J9,10=6.3 Hz, H9(ß)], 3.491 [1H, ddd, J10,1,=10.2, J10,9=6.0, J10,1,=3.7 Hz, H10(α)], 4.304 [1H, ddd, J10,1,=10.0, J10,9=,6.1, J10,1,=4.3 Hz, H10(ß)], 5.02-5.18 (2H, m, H3'), 5.249 [1H, s, H12(α)], 5.332 [1H, s, H12(ß)], 5.73-6.17 (1H, m, H2'). 13C NMR spectrum (50 MHz, CDCI3) δ 12.99 [9-CH3(ß)], 13.60 [9-CH3(α)], 20.20 [6-CH3(ß)], 20.33 [6-CH3(α)], 21.51 (CH2), 24.72. (CH2), 24.90 (CH2), 26.09 (3-CH3), 30.21 [C9(ß)], 31.03 [C9(α)], 34.23 [C7(ß)], 34.49 [C7(α)], 36.35 [C4(α)], 36.61 [C4(ß)], 37.16 (CH2), 37.40 [C6(α)], 37.49 [C6(ß)], 44.33 [C8a(ß)], 46.07 [C8a(α)], 52.00 [C5a(α)], 52.36 [C5a(ß)], 73.87 [C10(α)], 74.73 [C10(ß)], 80.70 [C12a(α)], 81.08 [C12a(ß)l, 89.10 [C12(ß)3, 92.02 [C12(α)], 103.14
[C3(ß)], 103.97 [C3(α)], 116.08 [C3' (ß)], 116.42 [C3' (α)], 134.92 [C2' (α)3, 136.48 [C2' (ß)] .
Example 12
e) Carboxybutyl Deoxoqinghaosu (13a), (13b)
Figure imgf000022_0001
Figure imgf000022_0002
The hydroxy acid (7a) (30.2mg; 93.7 μmol) was submitted to the same conditions as described in a). The resulting crude product was then fractionated by chromatography on silicic acid (ether/light petroleum, 50:50) to give the ß-epimer of carboxybutyl deoxoqinghaosu (13a) as a colourless viscous oil (11.9 mg; 34%). 1H NMR spectrum (200 MHz, CDCI3) δ 0.857 (3H, d, J9-Me,9=7.6 Hz, 9-CH3), 0.961 (3H, d, J6-Me,6=5.8 Hz, 6-CH3), 1.419 (3H, s, 3-CH3), 4.150 (1H, ddd, J10,1,=10.1, J10,9=6.2, J10r=2.2 Hz, H10), 5.298 (1H, s, H12). 13C NMR spectrum (50 MHz, CDCI3) δ 13.01 (9-CH3), 20.19 (6-CH3), 24.63, 24.63, 24.86 (C1', C5, C8), 26.10 (3-CH3), 27.03, 29.01 (C3', C2'), 30.26 (C9), 33.88 (C4'), 34.45 (C7), 36.57 (C4), 37.44 (C6), 44.39 (C8a), 52.36 (C5a), 75.37 (C10), 81.13 (C12a), 88.99 (C12), 103.22 (C3), 178.98 (C5'). Similarly, the hydroxy acid (7b) (18.3 mg; 57 μmol) was converted into the α-epimer of carboxybutyl deoxoqinghaosu (13b) (8.4 mg; 40%). 1H NMR spectrum (200 MHz, CDCl3) d 0.777 (3H, d, J9-Me,9=7.4 Hz, 9-CH3), 0.953 (3H, d, J6-Me,6=6-2 Hz, 6-CH3), 1.409 (3H, s, 3-CH3), 3.42 (1H, m, H10), 5.219 (1H, s, H12). Example 13
f) Dimethyl Deoxoqinghaosu (14)
Figure imgf000023_0001
The dimethyl alcohol (8) (53 mg; 0.21 mmol) was submitted to the same conditions as described in a). Dimethyl deoxoqinghaosu (14) was then isolated by flash chromatography on silica (ether/light petroleum/ 20:80) as a viscous oil which slowly crystallised (22 mg; 35%). 1H NMR spectrum (200 MHz, CDCl3) δ 0.887 (3H, d, J9-Me,9 = 7.5 Hz, 9-CH3), 0.959 (3H, d, J9-Me,6 = 5'8 Hz, 6-CH3), 1.228 (3H, s, 10-CH3), 1.325 (3H, s, 10-CH3), 1.424 (3H, s, 3-CH3), 1.36-1.93 (9H, m), 2.027 (1H, ddd, J = 14.4, J = 4.7, J = 3.1 Hz), 2.277 (1H, ddd, J = 13.9, J - 13.4, J = 4.0 Hz), 2.433 (1H, dq, J99,-Me = 7·5' J9,8a = 4.3 Hz, H9), 5.313 (1H, s, H12). 13C NMR spectrum (50 MHz, CDCI3) δ 13.9.6 (9-CH3), 20.41 (6-CH3), 20.76 (10-CH3), 23.81 (C8), 24.56 (C5), 26.32 (3-CH3), 31.91 (C9), 34.76 (C7), 35.68 (10-CH3), 36.58 (C4), 37.48 (C6), 46.28 (C8a), 52.80 (C5a), 76.3 - 77.6 (C10, obscured by CDCl3), 80.97
(C12a), 88.94 (C12), 103.84 (C3). Mass spectrum: m/z 264 (M-O2, 7%), 250 (28), 235 (17), 207 (17), 206 (17), 192 (73), 177 (100), 165 (32), 138 (48), 123 (24), 109 (24), 95 (28), 81 (23), 69 (37), 55 (52), 43 (95), 28 (21). Preparation of Dehydroqinghaosu Adducts
Example 14
a) With thiophenol
Figure imgf000024_0001
A solution of dehydroqinghaosu (17.6 mg; 62.7 μmol) in chloroform (2 ml) was treated with thiophenol (6.5 μl; 62.7 μmol) and triethylamine (4 μl) with cooling in an ice bath. The whole was then stirred at room temperature under nitrogen for 24 h. Aqueous workup afforded the phenylthio derivative (15) as a 1:2 mixture of ß- and α- epimers in essentially quantitative yield and free of byproducts (23.9 mg; 98%). 1H NMR spectrum (600 MHz, CDCl3) δ 0.992 [3H, d, JMe,6=6.3 Hz, 6-CH3(α)], 1.007 [3H, d, JMe,6=5.9 Hz, 6-CH3(ß)], 1.419 [3H, s, 3-CH3(ß)], 1.451 [3H, s, 3-CH3(α)], 2.272 [1H, ddd, J91>=9.4, J9,1,=3.4, J9,8a=1 Hz, H9 (a)], 2.834 [1H, dd, Jgem=13.7, J1,,9=11.8 Hz,
H1'(ß)], 3.139 [1H, dd, Jgem=13.8, J1,,9=11.7 Hz, H1'(α)],
3.446 [1H, ddd, J9,1,=11.8, J9,1,=5, J9,8a=5 Hz, H9 (ß)], 3.776
[1H, dd, Jgem=13.8, J1,,9=4.4 Hz, H1'(ß)], 3.860 [1H, dd,
Jgem=13.8, J1,,9=3.4 Hz, H1' (α)], 5.864 [1H, s, H12(ß)], 5.918 [1H, s, H12(α)], 7.18-7.40 (5H, m, SPh).
Example 15
b) With thioglycolic acid.
Figure imgf000024_0002
A solution of dehydroqinghaosu (14.4 mg; 51.4 μmol) in chloroform (2 ml) was treated with thioglycolic acid (3.6 ftl; 51.4 μmol) and triethylamine (7.2 μl; 51.4 μmol). The whole was stirred at room temperature under nitrogen for 3 d before being quenched with NaHCO3 solution (0.3 M). The resulting mixture was extracted with ether and then the aqueous phase was acidified (HCl, 0.1M) to pH 6. Extraction of the aqueous phase with ether followed by the usual workup afforded the adduct (16) as a 2:1 mixture of ß- and α-epimers (15.4 mg; 81%). These were separated by chromatography on silicic acid (ether/light petroleum, 60:40) as very hygroscopic fine white solids. First was obtained the ß-epimer. 1H NMR spectrum (200
MHz, CDCl3) δ 1.007 (3H, d, J9-Me,6 = 5.6 Hz, 6-CH3), 1.447
(3H, s, 3-CH3), 5.878 (1H, s, H12). Next was obtained the α-epimer. 1H NMR spectrum (200 MHz, CDCl3) δ 1.004
(3H, d, J6-Me,6 = 5.6 Hz, 6-CH3), 1.449 (3H, S, 3-CH3), 5.956 (1H, s, H12).
Example 16
c) With methyl thioglycolate .
Figure imgf000025_0001
Dehydroqinghaosu (16.7 mg; 59.5 μmol) was treated with methyl thioglycolate (5.3 μl; 59.5 μmol) and triethylamine (4 μl) in chloroform (2 ml) for 3 d as described above. The reaction mixture was evaporated to dryness and then fractionated by flash chromatography (ether/light petroleum, 50:50) to give the ß-epimer as the least polar fraction (13.8 mg; 60%) and as very fine needles, 1H NMR spectrum (200 MHz, CDCl3) δ 1.00 (3H, d, JMe,6=5.9 Hz, 6-CH3), 1.44 (3H, s, 3-CH3), 2.65 (1H, dd, Jgem=13.2, J1,,9=10.6 HZ, H1'), 3.21 (1H, d, Jgem=14.9 Hz, H1"), 3.32 (1H, d, Jgem=14.9 Hz, H1"), 3.40 (1H, dd, Jgem=13.1, J1,,9=5.0 Hz, H1'), 3.51 (1H, ddd, J9,1,=10.8, J9,1,=5 . 0 , J9,8a=5 Hz , H9 ) , 3 . 757 (3H, s , OCH3) , 5 . 871 (1H, s, H12), and the α-epimer (6.4 mg; 28%) as a viscous oil, 1H NMR spectrum (200 MHz, CDCl3) δ 1.00 (3H, d, J9-Me,6 = 5.3 Hz, 6-CH3), 1.45 (3H, s, 3-CH3), 1.2 - 2.5 (11H, m), 2.39 (1H, ddd, J9,1, = 11.2, J9,1, = 4.0, J9,8a = 1.2 Hz, H9), 3.00 (1H, dd, Jgem = 13.3, J1,,9 = 11.3 Hz, H1'), 3.25 (1H, d, Jgem = 14.9 Hz, H1"), 3.32 (1H, d, Jgem = 14.9 Hz, H1"), 3.41 (1H, dd, Jgem = 13.2, J1,,9 = 3.9 Hz, H1'), 3.74 (3H, s, OCH3), 5.95 (1H, s, H12) .
Example 17
d) With mercaptopropionic acid
Figure imgf000026_0001
A solution of dehydroqinghaosu (24.9 mg; 89 μmol) in chloroform (2 ml) was treated with mercaptopropionic acid
(7.8 μl; 89 μmol) and triethylamine (12.4 μl; 89 μmol) with stirring at room temperature under nitrogen for 24 h and then for a further 24 h allowing the solvent to slowly evaporate away. The whole was diluted with ether and washed with dilute HCl solution. The ether solution was dried (MgSO4) and evaporated to dryness to give the crude adduct which was submitted to chromatography on silicic acid (ether/light petroleum, 75:25). The first compound to be eluted was the ß-epimer which was obtained as a fine white solid (8.2 mg; 24%). % NMR spectrum (600 MHz, CDCl3) δ 1.008 (3H, d, J6-Me,6 = 5.7 Hz, 6-CH3), 1.041 - 1.155 (2H, m), 1.40 - 1.51 (4H, m), 1.445 (3H, s, 3-CH3), 1.76 - 1.83 (2H, m), 2.141 (1H, ddd, J = 13.0, J
= 4.6, J = 4.6 Hz), 2.42 - 2.47 (1H, m), 2.554 (1H, dd,
Jgem =13.5, J1,,9 =11.9 Hz, H1'), 2.67 - 2.70 (2H, m, 2 X
H2"), 2.79 - 2.81 (2H, m, 2 X H1"), 3.334 (1H, dd, Jgem =
13.6, J1,,9= 4-6 Hz, H1'), 3.449 (1H, ddd, J9,1, = 11.6, J9,1, = 4.8, J9,8a = 4.8 Hz, H9) , 5.865 (1H, s, H12) . Next was obtained the α-epimer as a viscous oil (24.5 mg; 71%) . 1H NMR spectrum (200 MHz, CDCl3) δ 1.060 (3H, d, J6-Me,6 = 5'8 Hz' 6"CH3) , 1-506 (3H, s, 3-CH3) , 1.15 - 2.61 (11H, m, 2 X H4, 2 X H5, H5a, H6, 2 X H7, 2 X H8, H8a),
2.355 (1H, ddd, J9,1, = 11.5, J9,1, = 3.7, J9,8a = 1.0 Hz, H9), 2.70 - 2.90 (4H, m, 2 XH1", 2 X H2") , 2.952 (1H, dd, J1,,1, = 13.3, J1,,9 = 11.6 Hz, H1'), 3.401 (1H, dd, J1,,1, = 13.3, J1,,9 - 3.7 Hz, H1'), 5.96 (1H, s, H12) . Example 18
e) With methyl mercaptopropionate
Figure imgf000027_0001
Dehydroqinghaosu (29.4 mg; 0.105 mmol) in chloroform (3 ml) was treated with methyl mercaptopropionate (11.6 μl; 0.105 mmol) and triethylamine (4 μl) with stirring as described above. After 48 h the whole was evaporated to dryness and the residue was submitted to flash chromatography (ether/light petroleum, 50:50) to give first the ß-epimer as a fine white solid (18.3 mg; 44%). 1H NMR spectrum 200 MHz, CDCl3) δ 1.01 (3H, J6-Me,6 = 5.8 Hz, 6-CH3), 1.45 (3H, s, 3-CH3), 1.0- 1.9 (6H, m), 2.0 - 2.2 (3H, m), 2.4 - 2.5 (2H, m), 2.54 (1H, dd, Jgem = 13.2, Jr 9 = 11.4 Hz, H1'), 2.59 - 2.67 (2H, m, 2 X H2"), 2.76 - 2.84 (2H, m, 2 X H1"), 3.33 (1H, dd, Jgem = 13.3, J1,,9 = 4.7 Hz, H1'), 3.44 (1H, ddd, J9,1, = 11.5, J9,1, = 4.9, J9,8a = 4.9 Hz, H9), 3.71 (3H, s, OCH3), 5.67 (1H, s, H12).13C
NMR spectrum (50 MHz, CDCl3) δ 19.76 (6-CH3), 22.97 (C7),
24.84 (C8), 25.12 (3-CH3), 26.98 (CH2), 28.86 (CH2), 33.30
(CH2), 34.41 (CH2), 35.83 (CH2), 37.51 (C6), 37.55 (C8a), 41.17 (C5a), 49.97 (C9), 51.83 (OCH3), 79.24 (C12a), 93.80 (C12), 105.49 (C3), 170.17 (COOCH3), 172.08 (C10). Next was obtained the α-epimer as a viscous oil (9.7 mg; 23%). 1H NMR spectrum (200 MHz, CDCl3) δ 1.00 (3H, d, J6_ Me,6 = 5.7 Hz, 6-CH3), 1.1 - 1.6 (5H, m), 1.45 (3H, s, 3- CH3), 1.65 -1.83 (2H, m), 1.69 -2.08 (2H, m), 2.14 (1H, br dd, Jgem = 13.7, J = 4.5 Hz), 2.29 (1H, ddd, J9,1, = 11.6, J9,1, = 3.7, J9,8a = 1.1 Hz, H9), 2.3 - 2.47 (1H, m), 2.59 - 2.67 (2H, m, 2 X H2"), 2.76 - 2.84 (2H, m, 2 X H1"), 2.88 (1H, dd, Jgem = 13.2, J1,,9 = 11.6 Hz, H1'), 3.33 (1H, dd, Jgem = 13.2, J1,,9 = 3.7 Hz, H1'), 3.70 (3H, s, OCH3), 5.95 (1H, s, H12). When the solvent was changed to dichloromethane the ß-epimer was obtained in only 15% yield and the α-epimer in 77% yield. Example 19
f) With thioglycerol
Figure imgf000028_0001
Dehydroqinghaosu (14.6 mg; 52 μmol) in chloroform (2 ml) was treated with thioglycerol (5.6 mg; 4.3 μl; 52 μmol) and triethylamine (4 μl). The whole was stirred at room temperature overnight after which time complete reaction had taken place. The reaction mixture was evaporated to dryness to give the crude ß- and α-epimeric adducts in a ratio of 2.2 : 1. These were separated by flash chromatography on silica (ethyl acetate/light petroleum, 80 : 20) to give first, the ß-epimer as a mixture of diastereomers at C2" and as a fine white solid (12.2 mg; 60%). 1H NMR spectrum (400 MHz, CDCl3) (*denotes other diastereomer) δ 1.012 (3H, d, J6-Me6 = 5-7 Rz, 6-CH3), 1.07 - 1.14 (2H, m), 2.00 - 2.18 (3H, m), 2.40 - 2.48 (1H, m), 2.54 - 2.74 (3H, m) , 3.320 (1H, ddd, J = 13.1, J = 7.9, J = 4.8 Hz) , *3.473 (1H, ddd, J9,1, = 11.2, J9,1, = 5.9, J9,8a = 3.6 Hz, H9) , 3.482 (1H, ddd, J9,1, = 10.9, J9,1, = 5.4, J98a = 5.4 Hz, H9) , *3.572 (1H, dd, J = 11.2, J = 5.8 Hz), 3.580 (1H, dd, J = 11.2, J = 5.9 Hz), 3.758 (1H, br ddd, J = 11.3, J = 3.0, J = 3.0 Hz) , 3.82 -3.88 (1H, m), 5.878 (1H, s, H12) . 13C NMR spectrum (50 MHz, CDCI3) δ 19.79 (6-CH3), 23.17 (C8) , 24.85 (C5) , 25.14 (3-CH3), 28.92, 29.72 (CH2), 30.94 (C9), 33.35 (C7), 35.87 (C6), 37.53 (CH), 37.80, 38.19 (CH) 41.52, 41.73 (CH), 50.01
(C5a), 65.29 (C3"), 69.74, 70.37 (C2"), 79.29 (C12a),
93.89 (C12), 105.59 (C3), 170.25 (C10). The α-epimer was obtained as a viscous oil and as a mixture of diastereomers at C2" (5.1 mg; 25%). 1H NMR spectrum (400 MHz, CDCl3) δ 1.009 (3H, d, J6-Me,6 = 6-1 Hz, 6-CH3), 1-16 - 1.34 (2H, m), 1.39 - 1.52 (2H, m), 1.452 (3H, s, 3-CH3), 1.70 - 1.82 (2H, m), 1.92 - 2.16 (3H, m), 2.31 - 2.43 (2H, m), 2.59 - 2.75 (3H, m), 2.933 (1H, ddd, J = 14.0, J = 11.1, J = 3.1 Hz), 3.329 (1H, ddd, J = 13.2, J = 13.2, J = 4.0 Hz), 3.55 - 3.60 (1H, m), 3.766 (1H, br d, J = 11.4 Hz), 3.81 - 3.89 (1H, m), 5.954 (1H, s, H12).
Example 20
g) With L-cysteine
Figure imgf000029_0001
L-Cysteine (5.8 mg; 36.8 μmol) was added as a solid to a stirred solution of dehydroqinghaosu (10.3 mg; 36.8 μmol) in methanol (1.5 ml) under nitrogen. Complete conversion to the adduct occurred almost immediately. The reaction mixture was then evaporated to dryness whereupon the crude residue was triturated with ether and the resulting fine white powder was obtained by filtration. The adduct (17), so obtained, was found to be only sparingly soluble in methanol and insoluble in most other solvents. Therefore, an estimate of the epimer ratio could not be made. 1H NMR spectrum (200 MHz, CD3OD) δ 0.87 [3H, d, JMe,6=6.4 Hz, 6-CH3(ß)], 1.006 [3H, d, J6-Me=5.8 Hz, 6- CH3(α)], 1.390 [3H, s, 3-CH3(ß)], 1.396 [3H, s, 3-CH3(α)], 2.821 [1H, dd, J1,,1,=12.9, J1,,9 = 10.0 Hz, H1'(ß)], 2.951 [1H, dd, J2",2" = 14.6, J2",1" = 8.5 Hz, H2"(α)], 2.966 [1H, dd, J2",2" = 14.4, J2",1" = 8.5 Hz, H2"(ß)], 3.167 [1H, dd, J2",2"= 14.6, J2",1" =4.0 Hz, H2"(α)], 3.191 [1H, dd, J2",2" = 14.4, J2",1" =4.0 Hz, H2"(ß)], 3.490 [1H, ddd, J9,1, = 10.0, J9,1,=5.4, J9,8 = 5.4Hz, H9(ß)], 3.702 [1H, dd, J1",2" = 8.6, J1",2" = 4.0 Hz, H1"(ß)], 3.749 [1H, dd, J1",2" = 8.4, J1",2" = 3.7 Hz, H1"(α)], 6.026 [1H, s, H12(ß)], 6.127 [1H, s, H12(α)]
Example 21
h) With N-acetyl-L-cysteine
Figure imgf000030_0001
Triethylamine (7.9 μl; 57 μmol) was added to a stirred solution of dehydroqinghaosu (15.9 mg; 57 μmol) and a suspension of N-acetyl-L-cysteine (9.3 mg; 57 μmol) in chloroform (3 ml). Deprotonation of the cysteine caused it to go into solution. The reaction mixture was stirred under nitrogen for 24 h and then for a further 24 h allowing the solvent to evaporate away slowly. Water was added and then the whole was extracted once with ether. The aqueous layer was separated and then acidified with 1 M hydrochloric acid in the presence of ether and extracted three times with more ether. The combined extracts were dried (MgSO4) and evaporated to dryness to give the cysteine adducts as a 1:1 mixture of α- and ß- epimers and as a viscous oil (18.9 mg; 75%). 1H NMR spectrum (200 MHz, CDCI3) δ 1.00 (3H, d, J6-Me,6 = 5.4 Hz, 6-CH3), 1.44 (3H, S, 3-CH3), 2.10 (3H, S, acetyl), 4.82 (1H, br m, Wh/2 = 15.7 Hz, N-H), 5.875 [1H, S, H12(ß)], 5.961 [1H, s, H12(α)], 6.822 (1H, dd, J2",1" = 7.9, J2",1" = 7.9 Hz, H2"), 7.45 (1H, br s, Wh/2 = 28.6 Hz, COOH).
Preparation of Ring-Contracted Analogues of Qinghaosu Derivatives
Example 22
a) Oxidative degradation of dihydroqinghao aldehyde (2)
Figure imgf000031_0001
A mixture of dihydroqinghao aldehyde (2) (105 mg; 0.48 mmol), DABCO (26 mg), cupric acetate monohydrate (50 mg) and 2,2' -bipyridyl (50 mg) in DMF (7 ml) was stirred for 12 h at 70-75° and then the solvent was removed under vacuum. The resulting residue was submitted to flash chromatography (ether/light petroleum, 1:5) to afford the ketone (23) as a colourless viscous oil (77 mg; 78%) [α]D 18-44.4° (c, 2.03, CHCI3). 1H NMR spectrum (400 MHz, CDCl3) δ 0.94 (3H, d, J=6 Hz), 1.65 (3H, s), 2.20 (3H,s), 2.95 (1H, br S), 4.48 (1H, s).
Example 23
b) Reduction
Figure imgf000031_0002
The ketone (23) (98 mg; 0.47 mmol) in methanol (3 ml) was treated with NaBH4, portionwise, at 0° until a t.l.c. monitor showed that the reaction was complete. Water was added and the whole was thoroughly extracted with ether. The combined ether extracts were washed with brine and dried (Na2SO4) and evaporated to dryness. The residue was then submitted to flash chromatography (ether/light petroleum, 2:8) to give the alcohols, (24a) and (24b) as a colourless viscous oil (98 mg; 99%) and as a 1:4 mixture of epimers. These were separated by h.p.l.c.
(ethyl acetate/light petroleum, 8:92, Whatman partisil 10
M9, semi-preparative) to give, firstly, epimer (24b)
[α]D 18-10.3° (c, 2.34, CHCl3). 1H NMR spectum (400 MHz,
CDCl3) δ 0.88 (3H, d, J=6 Hz), 1.24 (3H, d, J=6 Hz), 1.63 (3H, br s), 2.72 (1H, br s), 3.81 (1H, dq), 5.34 (1H, s).
The next to be eluted was epimer (24a) [α]D 18-8.5° (c,
1.68, CHCl3). 1H NMR spectrum (400 MHz, CDCl3) δ 0.89
(3H, d, J=6 Hz), 1.26 (3H, d, J=6.4 Hz), 1.62 (3H, br s),
2.46 (1H, br s), 3.775 (1H, dq), 5.14 (1H, s). Example 24
c) Oxygenation to deoxoqinghaosu analogues (25a) and (25b)
Figure imgf000032_0001
Figure imgf000032_0002
The major alcohol epimer (24b) (55.8 mg; 0.27 mmol) in acetonitrile (2 ml) and dichloromethane (1 ml) was irradiated under oxygen at -30° for 4 h in the presence of Rose Bengal sensitiser. The resulting hydroperoxide solution was then diluted with dichloromethane (7 ml) and treated with Cu(OTf)2 ( 0.027 mmol, 0.1 M in acetonitrile) as described for the preparation of the deoxoqinghaosu derivatives. The crude product mixture obtained after work-up was submitted to flash chromatography (ether/light petroleum, 1:6) to give the five membered ring analogue (25b) as a colourless viscous oil (19.1 mg; 28%) [α]D 20+120.2° (c, 1.1, CHCl3). 1H NMR spectrum (400 MHz, CDCI3) δ 0.98 (3H, d, J=6 Hz), 1.45 (3H, s), 1.47 (3H, d, J=6.5 Hz), 3.93 (1H, dq), 5.59 (1H, s). Similarly, the minor alcohol epimer (24a) (20 mg; 96 μmol) was converted into the five membered analogue (25a) (7.8 mg; 32%). 1H NMR spectrum (400 MHz, CDCl3) δ 0.98
(3H, d, J=6 Hz), 1.24 (3H, d, J=6.4 Hz), 1.44 (3H, s), 4.92 (1H, dq), 5.67 (1H,s).
Activity data
The testing results for the qinghaosu derivatives are as follows:
Ethyl deoxoqinghaosu has been tested against two strains of Plasmodium falciparum concurrently with artemether and sodium artesunate, the latter two compounds being in clinical use at the present time. The results are shown in the following graphs.
Kl strain from Kanchanaburi, Thailand (chloroquine resistant)
IC50 = 6.0 nM = 2.0 ng/ml
FC27 strain from Madang, Papua New Guinea (chloroquine sensitive)
IC50 = 4.3 nM = 1.3 ng/ml
In vitro effects of ethyldeoxoqinghaosu, artemether and artesunate against the FC27 strain of Plasmodium falciparum
Figure imgf000034_0001
In vitro effects of ethyldeoxoqinghaosu, artemether and artesunate against the K1 strain of Plasmodium falciparum
Figure imgf000034_0002
Effect of qinghaosu analogues on Toxoplasma gondii in vitro*
OHS Analogue IC50 (μM)
9 Deoxoqinghaosu 0.28 qinghaosu (natural compound) 0.9 qinghaosu (prepared from qinghao acid) 0.85
Dehydroqinghaosu sample 1 1.7
Dehydroqinghaosu sample 2 1.7
17 ß-epimer 2.2
19 ß-epimer 2.4
19 α-epimer 4.4
18 ß-epimer 4.8
18 α-epimer 14
Pyrimethamine (known compound) 1 * [3H]-uracil incorporation assay

Claims

Claims
1. Compounds of formula (I), pharmaceutically acceptable salts thereof or stereoisomeric forms thereof
Figure imgf000036_0001
wherein
l = 1, 2 or 3
n is an integer from 1-6
where X is independently selected from
H, =O,=CH2, aryl, COR, OR, COOR or
X = -(CR1R2)r-R3 where r is an integer from 1-10 and where r > 1, optionally at least 1 carbon atom can be replaced by O, S or N;
R1, R2 and R3 are independently selected from
H; alkyl, alkenyl, alkynyl, aryl, each optionally substituted by one or more substituents selected from alkyl, alkenyl, alkynyl, aryl, halogen, OR, CF3, NO2, COOR, NRR', SR, COR, CONRR' , SO3R, SO2NRR' , SR, SOR, and SO2R, where R and R' are independently selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl or optionally substituted arylalkyl wherein the optional substituents are as defined above; provided that (C)1-(X)n is not -CH2-CH(CH3)-.
2. A process for preparing compounds of formula (I), pharmaceutically acceptable salts thereof or stereoisomeric forms thereof comprising:
(A) carrying out at least one addition reaction on a compound of formula (II) having a -C=O functionality
Figure imgf000037_0001
to provide another compound of formula (II) with an alcoholic functionality at the (C)l-(V)r group and then followed by oxygenation to give a compound of formula (I);
where V is as defined for X; r and 1 are as defined above ;
(B) directly oxygenating a compound of formula (II) where there is a carboxylic functionality at the (C)l-(V)r reactive chain and also a further functional group to facilitate subsequent addition reaction, to provide compounds of formula (I) and then carrying out a suitable addition reaction to provide the required side chain; or
(C) for compounds of formula (I) where 1=1; carrying out one or more of the following steps on a compound of general formula (II):
(i) oxidative degradation and
(ii) reduction followed by oxygenation to give compounds of formula (I).
3. A process according to claim 2 wherein the oxygenation step in process A, B or C comprises (i) initial irradiation under oxygen in the presence of a catalyst such as Rose Bengal and
(ii) further oxygenation by treatment with a transition metal catalyst.
4. A process according to claim 3 wherein the transition metal catalyst is one or more selected from
Cu(OSO2CF3)2, copper(II) carboxylic salts and iron(III) salts.
5. A process according to claim 4 wherein the Cu(II) carboxylic salt is Cu(II) propionate or copper(II) 2-ethylhexanoate and the iron (III) salt is Fe(phenanthroline)3(PF6)3.
6. A process according to claim 5 wherein process step A comprises (i) treatment of the aldehyde 2 with A-MgBr, where A is alkyl, aryl or alkenyl to provide the respective derivatives;
followed by oxygenation to provide a compound of formula (I); (ii) treatment of
Figure imgf000038_0001
with MeMgI to provide
Figure imgf000039_0001
followed by oxygenation to provide a compound of formula (I); or
(iii) treatment of the aldehyde 2 with (EtO)2CH-A- MgBr where A is alkyl;
followed by hydrolysis and then oxidation to the HO(O=)C-A derivative;
followed by oxygenation to provide a compound of formula (I).
7. A process according to claim 5 wherein in process B the starting compound of formula (II) is dehydroqinghao acid which is oxygenated to provide dehydroqinghaosu and the addition reaction is carried out by treating dehydroqinghaosu with thiol nucleophiles.
8. A process according to claim 7 wherein the thiol nucleophile is thiophenol, thioglycolic acid, methyl thioglycolate, mercaptopropionic acid, methyl mercaptopropionate, thioglycerol, L-cysteine or N-acetyl-L-cysteine.
9. A process according to claim 5 wherein process (C) comprises
(i) oxidative degradation of aldehyde 2
(ii) reduction to the alcohol
(iii) followed by oxygenation to provide a compound of formula (I).
10. Compounds of general formula (II)
Figure imgf000040_0001
wherein V is as defined for X; r and l are as hereinbefore defined; provided that the (C)l-(V)r group is not CH(CH3)CH2OH and CH(CH3)C(=O)H.
11. A pharmaceutical composition comprising a compound of formula (I), a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof in a pharmaceutically acceptable carrier and/or diluent.
12. A method of treatment or prophylaxis of parasitic or viral diseases in a mammal comprising administering to the mammal a compound of formula (I), a pharmaceutically acceptable salt thereof or a stereoisomeric form thereof.
13. Use of a compound of formula (I), a pharmaceutically acceptable salt thereof or a stereoisomeric form thereof in the manufacture of a medicament for the treatment or prophylaxis of parasitic or viral diseases.
14. A compound of formula (I) substantially as herein described with reference to any one of examples 9-21 or 24.
PCT/AU1992/000548 1991-10-14 1992-10-14 Cyclic peroxyacetal compounds WO1993008195A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU27672/92A AU659505B2 (en) 1991-10-14 1992-10-14 Cyclic peroxyacetal compounds
JP5507280A JPH07500325A (en) 1991-10-14 1992-10-14 Cyclic peroxyacetal compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPK887591 1991-10-14
AUPK8875 1991-10-14

Publications (1)

Publication Number Publication Date
WO1993008195A1 true WO1993008195A1 (en) 1993-04-29

Family

ID=3775744

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1992/000548 WO1993008195A1 (en) 1991-10-14 1992-10-14 Cyclic peroxyacetal compounds

Country Status (3)

Country Link
JP (1) JPH07500325A (en)
AU (1) AU659505B2 (en)
WO (1) WO1993008195A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004026A1 (en) * 1998-07-14 2000-01-27 The Hong Kong University Of Science & Technology Trioxane derivatives
WO2000004024A1 (en) * 1998-07-14 2000-01-27 Bayer Aktiengesellschaft Antiparasitic artemisinin derivatives (endoperoxides)
WO2000004025A1 (en) * 1998-07-14 2000-01-27 The Hong Kong University Of Science & Technology Antiparasitic artemisinin derivatives (endoperoxides)
EP1043988A1 (en) * 1997-12-30 2000-10-18 Hauser Inc. C-10 carbon-substituted artemisinin-like trioxane compounds having antimalarial, antiproliferative and antitumour activities
US6156790A (en) * 1997-12-30 2000-12-05 Hauser, Inc. C-10 carbon-substituted artemisinin-like trioxane compounds having antimalarial, antiproliferative and antitumor activities
WO2001058888A1 (en) * 2000-02-10 2001-08-16 Motoyoshi Satake A sesquiterpenoic compound and pharmaceutical formulations comprising the same
US6297272B1 (en) 1999-01-12 2001-10-02 Hauser, Inc. Artemisinin analogs having antimalarial antiproliferative and antitumor activities and chemoselective methods of making the same
WO2004078762A1 (en) * 2003-01-23 2004-09-16 Jung Man-Kil Deoxoartemisinin analogs, process for their preparation, and anticancer agent comprising them

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988004660A2 (en) * 1986-12-18 1988-06-30 Sri International Synthesis process and oxygen-containing heterocyclic products thereof
AU4242189A (en) * 1988-10-04 1990-04-12 Hoechst A.G. Novel artemisinin derivatives, processes for their preparation and their use as antiprotozoal agents
AU6447590A (en) * 1989-09-27 1991-04-28 Rhone-Poulenc Rorer S.A. Cyclic peroxyacetal lactone, lactol and ether compounds
AU4467589A (en) * 1987-07-31 1991-08-01 Dermatologic Research Corporation Treatment of skin diseases with artemisinin and derivatives
AU7618591A (en) * 1990-05-07 1991-11-07 Hoechst Aktiengesellschaft 9-substituted compounds of 3 alpha, 11 alpha-epoxy-3,4,5,5a alpha,6,7,8,8a,9,11, 11a undecahydro-3 beta,6 alpa, 9-trimethylfurano(3,4-j)(1,2)-benzodioxepin, processes for their preparation and their use as antiprotozoal and antiviral agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988004660A2 (en) * 1986-12-18 1988-06-30 Sri International Synthesis process and oxygen-containing heterocyclic products thereof
AU4467589A (en) * 1987-07-31 1991-08-01 Dermatologic Research Corporation Treatment of skin diseases with artemisinin and derivatives
AU4242189A (en) * 1988-10-04 1990-04-12 Hoechst A.G. Novel artemisinin derivatives, processes for their preparation and their use as antiprotozoal agents
AU6447590A (en) * 1989-09-27 1991-04-28 Rhone-Poulenc Rorer S.A. Cyclic peroxyacetal lactone, lactol and ether compounds
AU7618591A (en) * 1990-05-07 1991-11-07 Hoechst Aktiengesellschaft 9-substituted compounds of 3 alpha, 11 alpha-epoxy-3,4,5,5a alpha,6,7,8,8a,9,11, 11a undecahydro-3 beta,6 alpa, 9-trimethylfurano(3,4-j)(1,2)-benzodioxepin, processes for their preparation and their use as antiprotozoal and antiviral agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TETRAHEDRON, Vol. 45, No. 23, 1989, YE BIN et al.: "Synthesis of Carba-Analogues of Qinghaosu", pages 7278-7290. *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043988A4 (en) * 1997-12-30 2001-10-31 Hauser Inc C-10 carbon-substituted artemisinin-like trioxane compounds having antimalarial, antiproliferative and antitumour activities
US6156790A (en) * 1997-12-30 2000-12-05 Hauser, Inc. C-10 carbon-substituted artemisinin-like trioxane compounds having antimalarial, antiproliferative and antitumor activities
US6160004A (en) * 1997-12-30 2000-12-12 Hauser, Inc. C-10 carbon-substituted artemisinin-like trioxane compounds having antimalarial, antiproliferative and antitumor activities
EP1043988A1 (en) * 1997-12-30 2000-10-18 Hauser Inc. C-10 carbon-substituted artemisinin-like trioxane compounds having antimalarial, antiproliferative and antitumour activities
US7452915B2 (en) * 1998-07-14 2008-11-18 The Hong Kong University Of Science And Technology Antiparasitic artemisinin derivatives (endoperoxides)
CN1122035C (en) * 1998-07-14 2003-09-24 拜尔公司 Antiparasitic artemisinin derivatives (endoperoxides)
US7439238B2 (en) 1998-07-14 2008-10-21 The Hong Kong University Of Science And Technology Antiparasitic artemisinin derivatives (endoperoxides)
EP1655302A3 (en) * 1998-07-14 2006-08-23 Bayer HealthCare AG Antiparasitic artemisinin derivatives (endoperoxides)
WO2000004025A1 (en) * 1998-07-14 2000-01-27 The Hong Kong University Of Science & Technology Antiparasitic artemisinin derivatives (endoperoxides)
WO2000004024A1 (en) * 1998-07-14 2000-01-27 Bayer Aktiengesellschaft Antiparasitic artemisinin derivatives (endoperoxides)
AU765860B2 (en) * 1998-07-14 2003-10-02 Hong Kong University Of Science And Technology, The Antiparasitic artemisinin derivatives (endoperoxides)
WO2000004026A1 (en) * 1998-07-14 2000-01-27 The Hong Kong University Of Science & Technology Trioxane derivatives
EP1655302A2 (en) * 1998-07-14 2006-05-10 Bayer HealthCare AG Antiparasitic artemisinin derivatives (endoperoxides)
US6984640B1 (en) 1998-07-14 2006-01-10 Bayer Aktiengesellschaft Antiparasitic artemisinin derivatives (endoperoxides)
US6297272B1 (en) 1999-01-12 2001-10-02 Hauser, Inc. Artemisinin analogs having antimalarial antiproliferative and antitumor activities and chemoselective methods of making the same
US6586464B2 (en) 1999-01-12 2003-07-01 Johns Hopkins University Artemisinin analogs having antimalarial, antiproliferative, and antitumor activities and chemoselective methods of making the same
WO2001058888A1 (en) * 2000-02-10 2001-08-16 Motoyoshi Satake A sesquiterpenoic compound and pharmaceutical formulations comprising the same
WO2004078762A1 (en) * 2003-01-23 2004-09-16 Jung Man-Kil Deoxoartemisinin analogs, process for their preparation, and anticancer agent comprising them
US7205332B2 (en) 2003-01-23 2007-04-17 Industry-Academic Cooperation Foundation, Yonsei University Deoxoartemisinin analogs, process for their preparation, and anticancer agent comprising them

Also Published As

Publication number Publication date
JPH07500325A (en) 1995-01-12
AU2767292A (en) 1993-05-21
AU659505B2 (en) 1995-05-18

Similar Documents

Publication Publication Date Title
US5489697A (en) Method for the preparation of (+)-calanolide A and intermediates thereof
US7696362B2 (en) Derivatives of artemisinin, and their uses in the treatment of malaria
US20020055528A1 (en) Artemisinin analogs having antimalarial, antiproliferative, and antitumor activities and chemoselective methods of making the same
WO1993008195A1 (en) Cyclic peroxyacetal compounds
WO2014020101A1 (en) Griseofulvin derivatives
CH680000A5 (en)
CA2253912C (en) Taxane derivatives, the preparation thereof and formulations containing them
FR2800374A1 (en) NEW DERIVATIVES OF 9- (3,5-DIMETHOXYPHENYL) -5,8,8A, 9- TETRAHYDROFURO [3 &#39;, 4&#39;: 6.7] NAPHTO [2,3-D] [1,3] DIOXOL-6 ( 5AH) - ONE, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US6136847A (en) Water-soluble trioxanes as potent and safe antimalarial agents
EP1687312B1 (en) Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof
FR2772765A1 (en) Benzo pyrano acridinone derivatives having antitumor activity
HU182048B (en) Process for preparing brendane derivatives and brendane analogues
EP0196943B1 (en) 8-thiotetrahydroquinoleine derivatives and their salts
JPH0352465B2 (en)
EP1297835B1 (en) Benzo[b]pyrano[3,2-h]acridin-7-one derivatives, processes for their preparation and pharmaceutical compositions thereof
JP4417256B2 (en) Single pot conversion from artemisinin to arteether
US7109327B2 (en) Total synthesis of galanthamine, analogues and derivatives thereof
US4730059A (en) 6&#39;-thiomethylsubstituted spectinomycins
ES2316555T3 (en) ADDITIONAL REACTIONS WITHOUT CATALYZE.
FR2795071A1 (en) NOVEL 7-OXO-2,3,7,14-TETRAHYDRO-1H-BENZO [B] PYRANO [3,2, H] ACRIDINE CARBOXYLATE DERIVATIVES, THEIR PREPARATION METHOD AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Williams et al. A new and efficient cyclization reaction to construct the bicyclomycin ring system: synthesis of N, N'-dimethyl-4-desmethylenebicyclomycin
KR0131997B1 (en) Antimalarial artemisinin derivatives
KR100440798B1 (en) Process for preparing non-acetal artemisinin derivative and 10-benzenesulfonyldihydroartemisinin
KR810000557B1 (en) Process for preparation of thiochroman derivatives
EP0043811A1 (en) Indolo-naphthyridines and their use as medicaments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA